Evidence map›Paper›PMID 39657742›Full record

ArticleThe Journal of antimicrobial chemotherapy2025

Establishment of epidemiological cut-off values of etimicin: a new fourth-generation aminoglycoside, against Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, Acinetobacter baumannii and Staphylococcus aureus.

Ge Zhang, Zhengyu Luo, Qiwen Yang, Wei Kang, Jingjia Zhang, Jin Li, Tong Wang, Jie Lin, Yunsong Yu, Chuyue Zhuo and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of antimicrobial chemotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Ge ZhangDepartment of Clinical Laboratory, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China.
Zhengyu LuoDepartment of Clinical Laboratory, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China.ORCID 0009-0005-2632-4892
Qiwen YangDepartment of Clinical Laboratory, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China.ORCID 0000-0001-7272-3900
Wei KangDepartment of Clinical Laboratory, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China.
Jingjia ZhangDepartment of Clinical Laboratory, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China.
Jin LiDepartment of Clinical Laboratory, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China.
Tong WangDepartment of Clinical Laboratory, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China.
Jie LinDepartment of Clinical Laboratory, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, China.
Yunsong YuZhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou, China.ORCID 0000-0003-2903-918X
Chuyue ZhuoDepartment of Infectious Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Chao ZhuoDepartment of Infectious Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Qihui WangDepartment of Laboratory Medicine, The First Hospital of China Medical University, Shenyang, Liaoning, China.
Yunzhuo ChuDepartment of Laboratory Medicine, The First Hospital of China Medical University, Shenyang, Liaoning, China.
Zhongju ChenClinical Microbiology Laboratory, Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China.
Ziyong SunClinical Microbiology Laboratory, Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China.
Dan GuoCenter for Biomedical Technology, National Infrastructures for Translational Medicine, Institute of Clinical Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.
Li ZhangDepartment of Clinical Laboratory, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China.
Yingchun XuDepartment of Clinical Laboratory, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China.

Funding

Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Sciences 2021-I2M-1-044National High Level Hospital Clinical Research Funding 2022-PUMCH-B-074
6 · The paper itself

Abstract

objectiveTo determine the epidemiological cut-off (ECOFF) values of etimicin against Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, Acinetobacter baumannii and Staphylococcus aureus.

methodsWe selected 1500 isolates from five hospitals throughout five cities in China spanning from January 2018 to December 2021 in the study. Minimal inhibit concentrations (MICs) of etimicin were determined using the broth microdilution method. ECOFFs of etimicin against six species were calculated using ECOFFinder software and visual estimation following EUCAST principles.

resultsMICs of etimicin were distributed from 0.064 to >128 mg/L for S. aureus, from 0.125 to >128 mg/L for P. aeruginosa, from 0.25 to >128 mg/L for K. pneumoniae, P. mirabilis and A. baumannii, and from 0.5 to >128 mg/L for E. coli. The MIC ECOFF of etimicin was 2 mg/L for K. pneumoniae, 8 mg/L for E. coli and P. mirabilis, 16 mg/L for P. aeruginosa and A. baumannii, and the tentative ECOFF (TECOFF) of etimicin was 2 mg/L for S. aureus.

conclusions(T)ECOFFs of etimicin against E. coli, K. pneumoniae, P. mirabilis, P. aeruginosa, A. baumannii and S. aureus were determined, which will be helpful to differentiate wild-type strains.

Indexed as

AminoglycosidesAnti-Bacterial AgentsAcinetobacter baumanniiChinaEscherichia coliHospitalsHumansKlebsiella pneumoniaeMicrobial Sensitivity TestsProteus mirabilisPseudomonas aeruginosaStaphylococcus aureusAminoglycosidesAnti-Bacterial Agents

Identifiers

PMID39657742
PMCPMC11787892

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.